Cequr raises $100m series-C

Previous investors Endeavour Vision, Schroder & Co and VI Partners also participated in the round.

The funding will be used for further clinical and regulatory compliance, as well as preparations for the product's commercial launch in 2016.

Previous fundung
Cequr closed its $27m series-B funding round in September 2013. Backers included Endeavour, VI Partners and other investors.

The company raised a CHF 31.7m series-A round from Endeavour, VI Partners, BMC Ventures and Schroder in February 2010.

Company
Cequr was founded in 2008 and is headquartered in Horw, with additional offices in Nordborg in Denmark and Marlborough in the US.

The business develops insulin delivery devices for people with type-2 diabetes. Cequr's main product, PaQ, is a wearable device that is designed to provide three days of consistent basal insulin delivery and on-demand bolus insulin delivery.

Basal insulin, also known as background insulin, is used to keep blood glucose levels steady at times of fasting. Bolus insulin is a dose taken specifically at meal times by a diabetic to keep blood glucose levels under control after a meal.

People
Dough Lawrence is the CEO of Cequr. Chris Evans chairs Arthurian Life Sciences.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Early-stage
• Switzerland